课题基金 / 基金详情

项目摘要

项目成果

Jian-Xing Ma的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目中的许多研究人员在他们的研究中使用糖尿病动物模型。链脲佐菌素(STZ)诱导的大鼠或小鼠糖尿病模型和遗传性糖尿病模型如Akita小鼠、db/db小鼠和Zuker大鼠等是研究糖尿病并发症的常用模型。然而,大多数糖尿病并发症的发生所需的糖尿病诱导和监测以及糖尿病动物的长期维持与大量的例行工作有关,例如注射剧毒化合物STZ、遗传糖尿病动物的基因分型、血糖测量、胰岛素注射和定期临床数据收集。这个核心的目标是为糖尿病的诱导提供集中化的服务, 维护和使用糖尿病动物,并促进糖尿病研究。在过去,我们在合作的基础上形成了一个集中化的糖尿病动物使用设施。我们计划扩大现有的糖尿病动物核心设施,为糖尿病研究社区提供更广泛的服务。核心将提供以下服务,所有PJI和导师在这个项目中,不收取额外费用:1)。在研究人员要求的大鼠或小鼠或转基因或基因敲除小鼠中注射STZ诱发糖尿病。2)。培育遗传性糖尿病小鼠和大鼠并进行基因分型。3)。通过测量高血糖来监测糖尿病,必要时注射胰岛素。4)。收集和记录糖尿病动物的临床数据,如体重、尿量等。通过测量尿白蛋白和肌酐浓度来监测糖尿病动物的肾功能。6)。根据用户要求,提供糖尿病动物专用饲料。7)。目的:在氧诱导视网膜病变(OIR)模型中诱导视网膜新生血管,该模型是增殖性糖尿病视网膜病变的常用模型。8)。进行专门的检测以评估糖尿病并发症。9)。为了解剖组织,建立糖尿病动物的组织库,并协调糖尿病动物的组织共享。这个糖尿病动物核心将帮助PJI进行他们的项目,并减少他们在诱导和维持糖尿病动物方面的常规工作。糖尿病动物组织的协调共享也将大幅减少动物模型的总体预算。除了目前的PJI和未来的PJI,这一核心还将使OUHSC的导师和整个糖尿病研究社区受益。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Many investigators in this project use diabetic animal models in their research. Streptozotocin (STZ)-induced diabetes in rats or mice and genetic diabetes models such as Akita mice, db/db mice and Zuker rats, etc, are commonly used models for studying diabetic complications. However, induction and monitoring of diabetes and maintenance of diabetic animals for long durations, as required for most diabetic complications to occur, are associated with tremendous amounts of routine work, such as injection of STZ which is a highly toxic compound, genotyping of genetic diabetic animals, blood glucose measurement, insulin injection and regular clinical data collection. The goal of this Core is to provide a centralized service for induction of diabetes, maintenance and use of diabetic animals and to facilitate diabetic research. In the past, we have formed a centralized diabetic animal use facility on a collaboration basis. We plan to expand this existing diabetic animal core facility and provide broader services to diabetic research community. The Core will provide the following services to all PJIs and Mentors in this project with no additional fees: 1). To induce diabetes by STZ injection in rats or mice or in transgenic or gene knockout mice required by investigators. 2). To breed and genotype genetic diabetic mice and rats. 3). To monitor diabetes by measuring hyperglycemia and inject insulin when necessary. 4). To collect and record clinical data from diabetic animals, such as body weight, urine volume, etc. 5). To monitor renal functions of diabetic animals by measuring albumin and creatinine concentrations in the urine. 6). To provide special diet for diabetic animals upon request by users. 7). To induce retinal neovascularization in the oxygen-induced retinopathy (OIR) model, a commonly used model for proliferative diabetic retinopathy. 8). To perform specialized assays to evaluate diabetic complications. 9). To dissect tissues, establish a tissue bank of diabetic animals and coordinate sharing of tissues from diabetic animals. This Diabetic Animal Core will assist the PJIs in their projects and reduce their routine work in induction and maintenance of diabetic animals. The coordinated sharing of diabetic animal tissues will also substantially reduce the overall budget for animal models. In addition to the current PJIs and future PJIs, this Core will also benefit the mentors and entire diabetes research community at OUHSC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dysregulation of PPARα in RPE degeneration
Sustained release of fenofibrate for the treatment of diabetic retinopathy
  • 批准号:
    10521702
  • 项目类别:
  • 资助金额:
    $55.18万
  • 财政年份:
    2022
  • 负责人:
    Jian-Xing Ma
  • 依托单位:
cGAS-STING signaling in diabetic retinopathy
Sustained release of fenofibrate for the treatment of diabetic retinopathy
  • 批准号:
    10684823
  • 项目类别:
  • 资助金额:
    $53.8万
  • 财政年份:
    2022
  • 负责人:
    Jian-Xing Ma
  • 依托单位:
海外基金